Related references
Note: Only part of the references are listed.Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial
Robert L. Gottlieb et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
D. M. Weinreich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Peter Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Noa Dagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit The INSPIRATION Randomized Clinical Trial
Parham Sadeghipour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
Renato D. Lopes et al.
LANCET (2021)
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Patrick R. Lawler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Ewan C. Goligher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
COVID-19 and its implications for thrombosis and anticoagulation
Jean M. Connors et al.
BLOOD (2020)
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Maximilian Ackermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
Alex C. Spyropoulos et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH
S. Kaatz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients REPLY
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)